↓ Skip to main content

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
19 tweeters

Citations

dimensions_citation
58 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Published in
Journal for Immunotherapy of Cancer, November 2019
DOI 10.1186/s40425-019-0793-8
Pubmed ID
Authors

Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro’, Federico Cappuzzo

Abstract

Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p <  0.0001; Cohort B: 13% versus 22%, p = 0.04), shorter progression free survival (PFS; Cohort A: 3.0 versus 4.0 months, p <  0.0001; Cohort B: 2.7 versus 5.2 months, p <  0.0001) and overall survival (OS; Cohort A: 7.4 versus 15.3 months, p <  0.0001; Cohort B: 5.0 versus 10.9 months, p < 0.0001). Moreover, BoM negatively affected outcome irrespective of performance status (PS; OS in both cohorts: p < 0.0001) and liver metastases (OS cohort A: p < 0.0001; OS Cohort B: p = 0.48). At multivariate analysis, BoM independently associated with higher risk of death (cohort A: HR 1.50; cohort B: HR 1.78). BoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy.

Twitter Demographics

The data shown below were collected from the profiles of 19 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 26%
Student > Master 6 14%
Other 4 9%
Student > Bachelor 4 9%
Professor 2 5%
Other 5 12%
Unknown 11 26%
Readers by discipline Count As %
Medicine and Dentistry 12 28%
Biochemistry, Genetics and Molecular Biology 9 21%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Computer Science 1 2%
Mathematics 1 2%
Other 2 5%
Unknown 15 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2019.
All research outputs
#2,566,432
of 20,470,279 outputs
Outputs from Journal for Immunotherapy of Cancer
#607
of 2,443 outputs
Outputs of similar age
#77,393
of 427,589 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#106
of 357 outputs
Altmetric has tracked 20,470,279 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,443 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 427,589 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 357 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.